Cerebral infarcts in the setting of eosinophilia: Three cases and a discussion

Archives of Neurology

Volumn 67, Issue 10, 2010, Pages 1275-1277

  Sethi, Hartej S ^a   Schmidley, James W ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IMATINIB; STEROID;

ADULT; ARTICLE; AXONAL NEUROPATHY; BONE MARROW BIOPSY; BRAIN ARTERY; BRAIN INFARCTION; CASE REPORT; CINEANGIOCARDIOGRAPHY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSARTHRIA; ELECTROCARDIOGRAM; EOSINOPHILIA; FECES ANALYSIS; FEMALE; FLACCID PARALYSIS; FLU LIKE SYNDROME; HEMISPHERE; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFERIOR MYOCARDIAL INFARCTION; LABORATORY TEST; LEG PAIN; LOW DRUG DOSE; LUNG EMBOLISM; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEDICAL RECORD REVIEW; MUSCLE BIOPSY; NEUROLOGIC EXAMINATION; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLURRED SPEECH; STROKE; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WEAKNESS;

ADULT; CEREBRAL INFARCTION; DIFFUSION MAGNETIC RESONANCE IMAGING; EOSINOPHILIA; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77957965840     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.256     Document Type: Article

References (14)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54(1):1-27.
2. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985;102(1):109-114.
3. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference: the idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982;97(1):78-92.
4. Chang WL, Lin HJ, Cheng HH. Hypereosinophilic syndrome with recurrent strokes: a case report. Acta Neurol Taiwan. 2008;17(3):184-188.
5. Ogbogu PU, Rosing DR, Horne MK III. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):457-475.
6. Sekiguchi M, Yu ZX, Take M, et al. Ultrastructural features of the endomyocardium in patients with eosinophilic heart disease: an endomyocardial biopsy study. Jpn Circ J. 1984;48(12):1375-1382.
7. Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood. 2007;109(3):995-1002.
8. Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol. 2008;126(3):e50-e52. (Pubitemid 351636340)
9. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000;86(1):110-113.
10. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006;107(2):558-565.
11. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133(5):468-492.
12. Kwon SU, Kim JC, Kim JS. Sequential magnetic resonance imaging findings in hypereosinophilia-induced encephalopathy. J Neurol. 2001;248(4):279-284.
13. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30(8):965-970.
14. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-916.